Alexander A Brescia1,2, Tessa M F Watt1,2, Francis D Pagani1,2, Thomas M Cascino2,3, Min Zhang4, Jeffrey S McCullough5, Supriya Shore3, Donald S Likosky1,2, Keith D Aaronson3, Michael P Thompson1,2. 1. Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. 2. Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. 3. Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor. 4. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor. 5. Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.
Abstract
Importance: While wide-scale adoption of durable left ventricular assist devices (LVADs) can be attributed to favorable randomized clinical trial outcomes, restrictive selection criteria may be associated with a lack of generalizability to real-world experience. Objective: To estimate the proportion of LVAD recipients who are eligible for clinical trials and to assess whether an association exists between trial eligibility and mortality. Design, Setting, and Participants: This cohort study examined 14 679 patients undergoing primary, intracorporeal continuous-flow LVAD implantation (with or without a right ventricular assist device) in 181 North American centers from January 1, 2012, to June 30, 2017, identified in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). To simulate a trial population, trial criteria from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Therapy With HeartMate 3 (MOMENTUM 3) were mapped to INTERMACS variables. Patients were categorized as eligible for trial inclusion or ineligible for trial inclusion and by number of ineligibility criteria met. Follow-up in INTERMACS was complete for all patients through October 31, 2017. Data were analyzed from July 2019 through November 2020. Exposures: Undergoing durable LVAD implantation. Main Outcomes and Measures: Trial eligibility and postimplant mortality were analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Results: Among 14 679 recipients, mean (SD) age was 57 (13) years, 11 503 individuals (78.4%) were men, and 11 406 individuals (77.7%) presented with New York Heart Association class IV heart failure. A total of 6429 recipients (43.8%) were ineligible for trial inclusion, of whom 4226 individuals (65.7%) met 1 ineligibility criterion, 1442 individuals (22.4%) met 2 criteria, and 761 individuals (11.8%) met 3 or more criteria. Estimated mortality for recipients who were trial-ineligible was higher than for recipients who were trial-eligible (1-year mortality: 25.3% [95% CI, 24.2%-26.5%] vs 16.2% [95% CI, 15.4%-17.1%]; 3-year mortality: 42.8% [95% CI, 41.3%-44.4%] vs 36.4% [95% CI, 35.0%-37.8%]; log-rank P < .001 for both). Patients who were trial-ineligible had increased risk of mortality compared with patients who were trial-eligible if they met 1 trial ineligibility criterion (hazard ratio [HR], 1.16 [95% CI, 1.08-1.24]; P < .001), 2 trial ineligibility criteria (HR, 1.51 [95% CI, 1.36-1.67]; P < .001), or 3 or more trial ineligibility criteria (HR, 2.09 [95% CI, 1.84-2.39]; P < .001). Among patients meeting only 1 ineligibility criterion, 4 criteria were independently associated with mortality: prior or ongoing mechanical circulatory support (HR, 1.63 [95% CI, 1.23-2.16]; P = .001), elevated creatinine level (HR, 1.42 [95% CI, 1.17-1.72]; P < .001), elevated bilirubin level (HR, 1.39 [95% CI, 1.17-1.66]; P < .001), and low albumin or prealbumin level (HR, 1.18 [95% CI, 1.05-1.33]; P = .007). Conclusions and Relevance: These findings suggest that while treatment for patients who are ineligible for LVAD trial inclusion should be weighed against medical management, more consideration could be given to designing trials with eligibility criteria that reflect real-world experience.
Importance: While wide-scale adoption of durable left ventricular assist devices (LVADs) can be attributed to favorable randomized clinical trial outcomes, restrictive selection criteria may be associated with a lack of generalizability to real-world experience. Objective: To estimate the proportion of LVAD recipients who are eligible for clinical trials and to assess whether an association exists between trial eligibility and mortality. Design, Setting, and Participants: This cohort study examined 14 679 patients undergoing primary, intracorporeal continuous-flow LVAD implantation (with or without a right ventricular assist device) in 181 North American centers from January 1, 2012, to June 30, 2017, identified in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). To simulate a trial population, trial criteria from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Therapy With HeartMate 3 (MOMENTUM 3) were mapped to INTERMACS variables. Patients were categorized as eligible for trial inclusion or ineligible for trial inclusion and by number of ineligibility criteria met. Follow-up in INTERMACS was complete for all patients through October 31, 2017. Data were analyzed from July 2019 through November 2020. Exposures: Undergoing durable LVAD implantation. Main Outcomes and Measures: Trial eligibility and postimplant mortality were analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Results: Among 14 679 recipients, mean (SD) age was 57 (13) years, 11 503 individuals (78.4%) were men, and 11 406 individuals (77.7%) presented with New York Heart Association class IV heart failure. A total of 6429 recipients (43.8%) were ineligible for trial inclusion, of whom 4226 individuals (65.7%) met 1 ineligibility criterion, 1442 individuals (22.4%) met 2 criteria, and 761 individuals (11.8%) met 3 or more criteria. Estimated mortality for recipients who were trial-ineligible was higher than for recipients who were trial-eligible (1-year mortality: 25.3% [95% CI, 24.2%-26.5%] vs 16.2% [95% CI, 15.4%-17.1%]; 3-year mortality: 42.8% [95% CI, 41.3%-44.4%] vs 36.4% [95% CI, 35.0%-37.8%]; log-rank P < .001 for both). Patients who were trial-ineligible had increased risk of mortality compared with patients who were trial-eligible if they met 1 trial ineligibility criterion (hazard ratio [HR], 1.16 [95% CI, 1.08-1.24]; P < .001), 2 trial ineligibility criteria (HR, 1.51 [95% CI, 1.36-1.67]; P < .001), or 3 or more trial ineligibility criteria (HR, 2.09 [95% CI, 1.84-2.39]; P < .001). Among patients meeting only 1 ineligibility criterion, 4 criteria were independently associated with mortality: prior or ongoing mechanical circulatory support (HR, 1.63 [95% CI, 1.23-2.16]; P = .001), elevated creatinine level (HR, 1.42 [95% CI, 1.17-1.72]; P < .001), elevated bilirubin level (HR, 1.39 [95% CI, 1.17-1.66]; P < .001), and low albumin or prealbumin level (HR, 1.18 [95% CI, 1.05-1.33]; P = .007). Conclusions and Relevance: These findings suggest that while treatment for patients who are ineligible for LVAD trial inclusion should be weighed against medical management, more consideration could be given to designing trials with eligibility criteria that reflect real-world experience.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Joseph G Rogers; Francis D Pagani; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Steven W Boyce; Samer S Najjar; Valluvan Jeevanandam; Allen S Anderson; Igor D Gregoric; Hari Mallidi; Katrin Leadley; Keith D Aaronson; O H Frazier; Carmelo A Milano Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Keith D Aaronson; Mark S Slaughter; Leslie W Miller; Edwin C McGee; William G Cotts; Michael A Acker; Mariell L Jessup; Igor D Gregoric; Pranav Loyalka; O H Frazier; Valluvan Jeevanandam; Allen S Anderson; Robert L Kormos; Jeffrey J Teuteberg; Wayne C Levy; David C Naftel; Richard M Bittman; Francis D Pagani; David R Hathaway; Steven W Boyce Journal: Circulation Date: 2012-05-22 Impact factor: 29.690
Authors: Mandeep R Mehra; Nir Uriel; Yoshifumi Naka; Joseph C Cleveland; Melana Yuzefpolskaya; Christopher T Salerno; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Steven W Hutchins; John Ransom; Gregory A Ewald; Akinobu Itoh; Nirav Y Raval; Scott C Silvestry; Rebecca Cogswell; Ranjit John; Arvind Bhimaraj; Brian A Bruckner; Brian D Lowes; John Y Um; Valluvan Jeevanandam; Gabriel Sayer; Abeel A Mangi; Ezequiel J Molina; Farooq Sheikh; Keith Aaronson; Francis D Pagani; William G Cotts; Antone J Tatooles; Ashok Babu; Don Chomsky; Jason N Katz; Paul B Tessmann; David Dean; Arun Krishnamoorthy; Joyce Chuang; Ia Topuria; Poornima Sood; Daniel J Goldstein Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Jeffrey J Teuteberg; Joseph C Cleveland; Jennifer Cowger; Robert S Higgins; Daniel J Goldstein; Mary Keebler; James K Kirklin; Susan L Myers; Christopher T Salerno; Josef Stehlik; Felix Fernandez; Vinay Badhwar; Francis D Pagani; Pavan Atluri Journal: Ann Thorac Surg Date: 2020-03 Impact factor: 4.330
Authors: Jennifer Cowger; Kartik Sundareswaran; Joseph G Rogers; Soon J Park; Francis D Pagani; Geetha Bhat; Brian Jaski; David J Farrar; Mark S Slaughter Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: Mandeep R Mehra; Yoshifumi Naka; Nir Uriel; Daniel J Goldstein; Joseph C Cleveland; Paolo C Colombo; Mary N Walsh; Carmelo A Milano; Chetan B Patel; Ulrich P Jorde; Francis D Pagani; Keith D Aaronson; David A Dean; Kelly McCants; Akinobu Itoh; Gregory A Ewald; Douglas Horstmanshof; James W Long; Christopher Salerno Journal: N Engl J Med Date: 2016-11-16 Impact factor: 91.245